KalVista Pharmaceuticals Inc. KALV
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
KalVista Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical needs, particularly hereditary angioedema (HAE). Its lead product, EKTERLY (sebetralstat), is an FDA-approved oral o…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees275
TickerKALV
Statistics
Market Cap$1.38B
Revenue (TTM)$110.2M
Net Income-$183.4M
Net Margin-166.5%
EPS$-3.69
P/E-7.31
P/S12.56
P/B-74.96
EV/EBITDA-10.38
ROE6766.7%
Dividend Yield—
Price$27.00
Data: Twelve Data · Revenue = mcap / P/S